

20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/AJ/2023-24/29

May 25, 2023

То,	То,
The Manager	The Manager
BSE Limited	National Stock Exchange of India Limited
Department of Corporate Services	Corporate Communication Department
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai – 400 001	Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol – Biocon

Subject: Newspaper Advertisement- Financial Results for the Quarter and Financial Year ended March 31, 2023

Dear Sir/Madam,

In continuation to our letter dated May 23, 2023 with regards to Financial Results for the quarter and year ended March 31, 2023, please find enclosed copies of newspaper advertisement published in Financial Express (English Language-All India Edition) and Vijayavani (Kannada-Bengaluru Edition) on May 25, 2023.

The above information is also available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

Mayank Verma
Company Secretary & Compliance Officer
Membership No.: ACS 18776

Enclosed: Copies of Newspaper advertisements

FINANCIAL EXPRESS

NSIC New MDBP Building, 2" Floor, Okhla Indl. Estate (Opp. NSIC Okhla Metro Station), New Delhi-110020 Open Tender Notice (e-Tendering mode only)

Online E-bids are invited for Design, Manufacture, Supply and Commissioning of 100 nos of 40 fee 3 Axle flat bed SEMI TRAILERs at CMLK Khatuwas terminal of CONCOR through Two packet e-tendering mode.

Tender No.CON/AREA-1/TECH/40/SEMI TRAILER-100/2023 Bid Reference Tendered Quantity 100 Nos. Estimated Cost Rs. 14,71,32,000/-Earnest Money Deposit (EMD)* Rs. 10 Lakhs through online payment gateway to CONCOR. Rs. 1,000/- through online payment gateway to CONCOR. Cost of Document Tender processing fee Rs. 4720/- (Inclusive of Taxes) through online payment (Non-refundable) From 25.05.2023 at 16:00 Hrs to 15.06.2023 at upto 17:00 Hrs Period of Tender Sale (online) Date and Time of Submission of Bid 16.06.2023 at 17:00 Hrs. Date and Time of opening of Bid 19.06.2023 at 11:00 Hrs.

For eligibility criteria and other details please log into www.concorindia.com or eprocure.gov.in o www.tenderwizard.com/CCIL. Bidders are requested to visit the website regularly. CONCOR reserve the right to reject any or all the tenders without assigning any reasons thereof. For complete details loging Group General Manager/T/Areawww.tenderwizard.com/CCIL.

भारतीय कंटेनर निगम लिमिटेड Container Corporation of India Ltd. Tender No. CON/A-II/CIVIL/AMC/T-I/2023 (NOTICE INVITING E- TENDER)

CONCOR invites E-Tender in Single Packet System of tendering for the following work:-Name of Work Repair and Maintenance Of Civil Work Of Corporate Office at C-3, Mathura Road NSIC-MDBP Building (2nd & 3rd Floor), CONCOR Officers Flats at Defence Colony, Jungpura, Khelgaon, San Martin Marg, Chanakyapuri, Technical Office at US Complex (Room No. 6,7,12 & 19), 27 Tilak Bridge Railway Colony New Delhi & Operational Office at Gurgaon.

Estimated Cost Rs. 276.08 Lakhs inclusive all taxes Completion Period 24 (Twenty Four) Months Earnest Money Deposit Rs. 2,88,100 /- (through e-payment) Cost of Tender Document Tender Processing Fee (Non-refundable) Rs. 4,720/- (inclusive all taxes & duties through e-payment Date of sale of Tender (online) 25.05.2023 (11:00 hrs) to 14.06.2023 (upto 17:00 hrs) Date & Time of submission of Tender 15.06.2023 upto 17:00 hrs Date & Time of Opening of Tender. 16.06.2023 at 11:30 hrs

refer to detailed tender notice available on website www.concorindia.com. but the complete tender document can be downloaded from website www.tenderwizard.com/CCIL only. Further, Corrigendum / Addendum to this Tender, if any, will be published on website www.concorindia. in, www.tenderwizard.com/CCIL and Central Procurement Portal (CPP) only. Newspaper press advertisement shall not be issued for the same.

For financial eligibility criteria, experience with respect to similar nature of work, etc., please


Executive Director (P&S)/A-II Phone No.: 011-41222500


0.73


8.04


'IMPORTANT


readers inquiries letters are not accepted in response to box number advertisement."











advertisers or otherwise acting on an advertisement in any manner whatsoever. Registered



SMS PHARMACEUTICALS LIMITED

CIN:L24239TG1987PLC008066

Registered office: Plot.No. 72 H.No. 8-2-334/3&4, Road No. 5 Opp. SBI Executive Enclave, Banjara Hills, Hyderabad, Telangana 500034 IN Phone.No: 040-35359999/25259999, website:www.smspharma.com; email complianceofficer@smspharma.com

Extract of audited Financial Results for the Quarter and year Ended 31st March, 2023

	(₹ in Lakhs)									
SI.	S. Pa-90940A VSSAR2		Stand	lalone			Conso	lidated	70502	
No.	Particulars	Quarte	r ended	Year	ended	Quarte	r ended	Year ended		
140.	NOTE OF THE PROPERTY OF THE PR	31.03.2023	31.03.2022	31.03.2023	31.03.2022	31.03.2023	31.03.2022	31.03.2023	31.03.2022	
1	Total Income from Operations (net)	14,942.55	6,091.90	52,205.14	51,987.43	14,942.55	6,091.90	52,205.14	51,987.43	
2	Profit from Ordinary Activities before Tax	1,064.27	(1,617.32)	554.96	6,865.47	1,063.40	(1,632.88)	534,91	6,849.91	
3	Profit from Ordinary Activities after Tax (after Extraordinary Items)	807.46	905.98	408.46	6,803.65	621.83	617.42	(705.93)	6,221.99	
4	Total Comprehensive Income for the quarter (comprising profit/Loss) for the quarter (after tax) and other comprehensive items)	783.39	924.76	387.93	6,807.58	598.76	635.05	(722.38)	6,230.00	
5	Equity Share Capital (Face value of share: Re.1/- each)	846.52	846.52	846.52	846.52	846.52	846.52	846.52	846.52	
6	Reserves (excluding Revaluation Reserve as per Balance Sheet) Re. 1/- each			48,663.47	48,529.50			45,206.00	46,182.34	
7	Earnings per share (before extraordinary items - (Not annualized)					2.				

1.07

0.48

Quarter Ended

Notes:

Basic/Diluted (in Rs)

1. The above Standalone and consolidated Financial Results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meetings held on

0.95

- 2. These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed Under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3. The above is an extract of detailed format of quarterly / annual financial results filed with the stock exchanges under regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of quarterly / annual financial results are available on the website of the Stock Exchanges of BSE; www.bseindia.com(ID 532815) or NSE; www.nseindia.com (Symbol SMSPHARMA) and companies website (www.smspharma.com).

By and on behalf of Board of Directors **SMS Pharmaceuticals Limited** Sd/-

0.73

(0.83)

7.35

Place: Hyderabad Date: 24-05-2023 Ramesh Babu Potluri (DIN: 00166381) Chairman and Managing Director

JORABAT SHILLONG EXPRESSWAY LIMITED Registered Office: The IL&FS Financial Center, Plot C-22, G Block, Bandra Kurla Complex,

Bandra (East). Mumbai- 400051. India Tel: 022-26533333 Fax: 022-26523979 Website: https://www.itnlindia.com/JSEL-SPV.aspx CIN:- U45203MH2010PLC204456 Extract of Audited Financial Results for the Year ended March 31, 2023

> (Rs. in Lakhs) Year Ended

100		Quarter Ended			Teal Lilded		
	Particulars	March 31, 2023 (Unaudited)	December 31, 2022 (Unaudited)	March 31, 2022 (Unaudited)	March 31, 2023 (Audited)	March 31, 2022 (Audited)	
1	Total Income from Operations	3,797	3,169	3,376	12,420	10,921	
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	2,871	2,808	(132)	9,008	(132)	
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	2,871	2,808	(132)	9,008	(132)	
4	Net Profit / (Loss) for the year after tax (after Exceptional and/or Extraordinary items)	2,871	2,808	(132)	9,008	(132)	
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the year (after tax) and Other Comprehensive Income (after tax)	2,871	2,808	(132)	9,008	(132)	
6	Paid-up equity share capital (face value - ₹10 per share)	8,400	8,400	8,400	8,400	8,400	
7	Reserves (excluding revaluation Reserve)	(13,839)	(16,710)	(22,847)	(13,839)	(22,847)	
8	Securities Premium Amount	-	-	-	2	-	
9	Net worth	(5,439)	(8,310)	(14,447)	(5,439)	(14,447)	
10	Paid-up Debt Capital	133,169	133,169	133,169	133,169	133,169	
11	Outstanding Redeemable Preference Shares	-				-	
12	Debt/Equity Ratio (number of times)	(24.48)	(16.02)	(9.22)	(24.48)	(9.22)	
13	Earnings per share (of ₹ 10/- each): (* Not annualised)				- 1		
	(a) Basic	3.42*	3.34*	3.18*	10.72	(0.16)	
3	(b) Diluted	3.42*	3.34*	3.18*	10.72	(0.16)	
14	Capital Redemption Reserve	-	-	-	-	-	
15	Debenture Redemption Reserve	8,162	8,162	8,162	8,162	8,162	
16	Debt Service Coverage Ratio (DSCR) (number of times)	((-		- 1	-	
17	Interest Service Coverage Ratio (ISCR) (number of times)	-	-	-	-	-	
Notes		56			10		

- The above is an extract of the detailed format of quarterly and yearly results filed with Stock Exchange under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015. The full format of the quarter and year ended financials results are available on the websites of the National Stock Exchange (NSE) -www.nseindia.com and the Company's - www.itnlindia.com/JSEL-SPV.aspx
- 2 For the items referred in regulation 52 (4) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchange (NSE) and can be accessed on the (www.nseindia.com) and on the Company's website - www.itnlindia.com/JSEL-SPV.aspx
- The above results are in compliance with Indian Accounting Standards ("Ind AS") notified by the Ministry of Corporate Affairs, read with SEBI Circular No. CIR/IMD/DFI/69/2016 dated August 10, 2016 4 The above financial results of the Company were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 24, 2023 and has been reviewed by the Statutory Auditor of the Company

For and on behalf of the Board

Rajnish Saxena

(₹ In Crore except as stated)

Date: May 24, 2023

Non-Executive Director DIN: 05188337

INDIA GLYCOLS LIMITED

Regd. Office: A-1, Industrial Area, Bazpur Road, Kashipur - 244 713, Distt. Udham Singh Nagar (Uttarakhand) Phones: +91 5947 269000/269500, Fax: +91 5947 275315/269535

Email: compliance.officer@indiaglycols.com, Website: www.indiaglycols.com • CIN: L24111UR1983PLC009097

Audited Financial Results for the Quarter & Year ended March 31, 2023

			S	TANDALONE	8			CC	DNSOLIDATE	D	
SI.	B. W. L.	Quarter Ended			Year Ended		Quarter Ended			Year Ended	
No.	Particulars	31.03.2023 (Audited)	31.12.2022 (Unaudited)	31.03.2022 (Audited)	31.03.2023 (Audited)	31.03.2022 (Audited)	31.03.2023 (Audited)	31.12.2022 (Unaudited)	31.03.2022 (Audited)	31.03.2023 (Audited)	31.03.2022 (Audited)
1	Total income from operations	1,619.74	1,532.48	1,498.34	6,668.45	6,622.86	1,620.12	1,531.41	1,498.97	6,665.53	6,622.95
2	Profit before Interest, depreciation and Tax (EBDITA)	100.93	80.55	85.77	325.11	278.90	100.48	76.14	84.42	319.42	276.74
3	Net profit/(Loss) for the period (before Tax, Exceptional and/or extraordinary items)	45.90	34.15	49.85	140.27	140.75	44.33	27.48	45.38	125.50	126.79
4	Net profit/(Loss) for the period before tax (after Exceptional and/or extraordinary items)	45.90	16.58	10.60	122.70	341.38	45.64	53.26	31.82	165.00	369.01
5	Net profit/(Loss) for the period after tax (after Exceptional and/or extraordinary items)	40.10	13.35	19.02	98.74	275.12	39.84	50.03	67.08	141.04	329.58
6	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	40.41	13.36	18.93	99.08	285.32	40.58	50.10	66.90	141.44	339.38
7	Equity Share Capital	30.96	30.96	30.96	30.96	30.96	30.96	30.96	30.96	30.96	30.96
8	Other Equity as shown in the Audited Balance Sheet				1,556.65	1,480.80				1,870.46	1,760.94
9	Earnings Per Share (of ₹ 10/- each) (Not Annualised) - Basic & Diluted (In ₹)	12.95	4.31	6.14	31.89	88.86	12.87	16.16	21.67	45.55	106.45

Note:

Place: Noida

Date: 24th May, 2023

- 1. The above is an extract of the detailed format of Quarterly/Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Yearly Financial Results are available on the Stock Exchanges Websites (www.bseindia.com and www.nseindia.com) and on the Company's website (www.indiaglycols.com).
- 2. The Board of directors have recommended a dividend @ ₹ 7.50/- per share of face value of ₹ 10/- each subject to the approval of the members of the Company at its ensuing Annual General Meeting.

for INDIA GLYCOLS LIMITED Sd/-

U.S. BHARTIA

Chairman and Managing Director DIN: 00063091



SS Biocon

EXTRACT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 202 (Rs. in Million, except per equity share data 3 months ended Year anded Year anded

3 months ended

31.12.2023

Audited

Year ended

31.03.2023

Audited

Year ended

31.03.2022

Audited

(Rs. In Lakhs except per share data)

3 months ended 31.12.2023	31.03.2023	Year ended 31.03.2022
Audited	Audited	Audited
37,739	1,11,742	81,840
4,996	11,885	10,942
4,966	8,971	9,831
3,132	4,627	6,484
2,503	5,765	7,451
6,003	6,003	6,003
	1,72,657	78,313
(not annualised)	(annualised)	(annualised)
2.62	3.88	5.44
2.62	3.87	5.42
	31.12.2023 Audited 37,739 4,996 4,966 3,132 2,503 6,003 (not annualised) 2.62	31.12.2023 31.03.2023 Audited Audited 37,739 1,11,742 4,996 11,885 4,966 8,971 3,132 4,627 2,503 5,765 6,003 6,003 1,72,657 (not annualised) (annualised) 2.62 3.88

Revenue from operations 5,067 19,929 17,382 Profit before tax 17,961 29,712 1,397 Net Profit for the period 18,108 28,484 861

Particulars

Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on May 23, 2023. The reports of the statutory auditors are unqualified. 3. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure

The audited standalone and consolidated financial results for the quarter and year ended March 31, 2023 in respect of Biocon Limited ('the

Requirements) Regulations, 2015. The above is an extract of the detailed format of audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the audited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.biocon.com

Svatantra Microfin Private Limited

svatantra Regd. Office: Sunshine Tower, Level 20, Senapati Bapat Marg, Elphinstone Road, Mumbai - 400013 Website: www.svatantramicrofin.com Email: secretarial@svatantra.adityabirla.com. CIN: U74120MH2012PTC227069 [Regulation 52 (8), read with Regulation 52 (4), of the SEBI (LODR) Regulations, 2015] Extract of Audited Financial Results for the quarter and financial year ended 31 March 2023

		Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
Sr. No.	Particulars	31/03/2023	31/12/2022	31/03/2022	31/03/2023	31/03/2022
4	100	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	37,154	38,410	25,036	136,697	81,97
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	7,966	3,585	4,565	17,224	6,30
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	7,966	3,585	4,565	17,224	6,30
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	6,057	2,678	3,514	12,977	4,72
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	6,058	2,680	3,517	13,000	4,68
6	Paid up Equity Share Capital	25,205	25,205	25,205	25,205	25,20
7	Reserves (Excluding Revaluation Reserve)	24,261	18,183	11,213	24,261	11,21
8	Securities Premium Account	4	4	4	4	
9	Net worth (including Compulsory Convertible Non-Cumulative Preference Shares)	114,966	103,888	86,918	114,966	86,91
10	Paid up Debt Capital / Outstanding Debt	626,058	562,672	480,434	626,058	480,43
11	Outstanding Redeemable Preference Shares	*	*		85	
12	Debt Equity Ratio	5.45	5.42	5.53	5.45	5.5
13	Earnings Per Share (of Rs. 10 /- each)					
	1. Basic:	0.80	0.38	0.64	1.78	0.8
5 8	2. Diluted:	0.80	0.38	0.64	1.78	0.8
14	Capital Redemption Reserve	NA.	NA.	NA	NA	N.
15	Debenture Redemption Reserve	NA.	NA	NA	NA	N.
16	Debt Service Coverage Ratio	NA.	NA	NA	NA	N
17	Interest Service Coverage Ratio	NA.	NA.	NA	NA	N.

Note: a) The above is an extract of the detailed format of audited Financial Results filed with BSE Limited under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the audited Financial Results is available on the

website of BSE (www.bseindia.com) and on the Company's website (www.svatantramicrofin.com). b) For the other line items referred in regulation 52(4) of the LODR Regulation, pertinent disclosures have been made to the BSE and can be accessed on the website of BSE (www.bseindia.com) and on the Company's website (https://svatantramicrofin.com).

By order of the Board For Svatantra Microfin Private Limited

Place: Mumbai Date: 23.05.2023 Ms. Ananyashree Birla (Director) DIN: 06625036

(₹ in lakh)



ICRA Limited

Corporate Identity Number (CIN): L74999DL1991PLC042749 Registered Office: B-710, Statesman House, 148, Barakhamba Road, New Delhi-110001 Telephone No.: +91-11-23357940; Website: www.icra.in; Email ID: investors@icraindia.com EXTRACT OF STANDALONE AUDITED FINANCIAL RESULTS FOR

THE QUARTER AND YEAR ENDED MARCH 31, 2023 0 - 1 - 1 - 0 - 1 -

S. No.	Particulars	Quarter ended March 31, 2023 (Audited)	Year ended March 31, 2023 (Audited)	Quarter ended March 31, 2022 (Audited)	Year ended March 31, 2022 (Audited)
1	Total income from operations	6,187.80	22,253.79	5,235.65	19,473.14
2	Net profit / (loss) for the period (before tax, exceptional and/or extraordinary items)	3,104.79	11,713.23	2,643.98	9,334.87
3	Net profit / (loss) for the period before tax (after exceptional and/or extraordinary items)	3,104.79	11,713.23	2,643.98	9,334.87
4	Net profit/ (loss) for the period after tax (after exceptional and/or extraordinary items)	2,414.74	9,592.90	1,876.63	7,330.93
5	Total comprehensive income for the period [comprising profit / (loss) for the period (after tax) and Other comprehensive income (after tax)]	2,412.30	9,551.35	1,901.17	7,378.13
6	Equity share capital	965.12	965.12	965.12	965.12
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet	72,693.48	72,693.48	65,513.30	65,513.30
8	Earnings per share (of ₹ 10/- each)				
	Basic :	25.11	99.73	19.51	76.21
	Diluted:	25.11	99.73	19.51	76.21

EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023

Quarter

Quarter Year ended

(₹ in lakh)

S. No.	Particulars	March 31, 2023 (Audited)	March 31, 2023 (Audited)	March 31, 2022 (Audited)	March 31, 2022 (Audited)
1	Total income from operations	10,908.06	40,323.08	9,370.93	34,280.52
2	Net profit / (loss) for the period (before tax, exceptional and/or extraordinary items)	5,087.69	18,121.74	4,654.35	15,208.63
3	Net profit / (loss) for the period before tax (after exceptional and/or extraordinary items)	5,087.69	18,121.74	4,654.35	15,208.63
4	Net profit/ (loss) for the period after tax (after exceptional and/or extraordinary items)	3,862.85	13,672.53	3,373.35	11,353.24
5	Total comprehensive income for the period [comprising profit / (loss) for the period (after tax) and Other comprehensive income (after tax)]	3,836.96	13,509.71	3,374.99	11,315.54
6	Equity share capital	965.12	965.12	965.12	965.12
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet	94,062.99	94,062.99	83,395.91	83,395.91
8	Earnings per share (of ₹ 10/- each)				
	Basic :	39.89	140.59	34.73	116.74
	Diluted:	39.89	140.59	34.73	116.74

The above is an extract of the detailed format of Quarterly and Yearly Standalone and Consolidated Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Statutory Auditors of the Company have carried out audit of the Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2023. The full format of the Quarterly Standalone and Consolidated Audited Financial Results and Audit Report thereon are available on the Stock Exchange websites at www.nseindia.com and www.bseindia.com and under the Investors section on the Company's website www.icra.in.

By Order of the Board of Directors

Ramnath Krishnan

Managing Director & Group C.E.O. (DIN: 09371341)

financialexp.ep. . in







Place: Mumbai

Date: May 24, 2023


BENGALURU

ended

5/25/23, 4:49 PM about:blank







EXTRACT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023

(Rs. in Million, except per equity share data)

	Particulars	3 months ended 31.12.2023 Audited	Year ended 31.03.2023 Audited	Year ended 31.03.2022 Audited
	Revenue from operations	37,739	1,11,742	81,840
Ш	Profit before exceptional items and tax	4,996	11,885	10,942
-	Profit before tax	4,966	8,971	9,831
IV	Profit attributable to shareholders of the Company	3,132	4,627	6,484
٧	Total comprehensive income attributable to shareholders of the Company	2,503	5,765	7,451
VI	Paid-up equity share capital [Face value of Rs. 5 each]	6,003	6,003	6,003
VII	Reserve [Excluding Revaluation Reserve] as shown in the audited balance sheet		1,72,657	78,313
VIII	Earnings per share [of Rs. 5 each]	(not annualised)	(annualised)	(annualised)
	(a) Basic	2.62	3.88	5.44
	(b) Diluted	2.62	3.87	5.42

1. Key standalone financial information

Particulars		3 months ended 31.12.2023	Year ended 31.03.2023	Year ended 31.03.2022
		Audited	Audited	Audited
Ι	Revenue from operations	5,067	19,929	17,382
Ш	Profit before tax	17,961	29,712	1,397
Ш	Net Profit for the period	18,108	28,484	861

- The audited standalone and consolidated financial results for the quarter and year ended March 31, 2023 in respect of Biocon Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on May 23, 2023. The reports of the statutory auditors are unqualified.
- 3. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 4. The above is an extract of the detailed format of audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the audited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.biocon.com.

Bengaluru Edition May 25, 2023Page No. 2 Powered by : eReleGo.com

about:blank 1/1